Table 1 Defining AR positivity across breast cancer samples
From: Androgen receptor function and targeted therapeutics across breast cancer subtypes
References | ER status | HER2 status | Primary/metastatic | Antibody | AR+ definition | AR+ samples (%) | Total |
|---|---|---|---|---|---|---|---|
Agrawal et al. [62] | ER+/ER− |  ±  | Primary Only | AR411 DAKO | Not Reported | 212 (43) | 488 |
Gonzalez et al. [63] | ER+/ER− | Not reported | Primary & Lymph Node Metastases | AR411 DAKO |  ≥ 1% | 83 (75) | 111 |
Micello et al. [41] | ER− and PgR− |  ±  | Primary Only | AR27 Novocastra |  ≥ 1% Nuclear | 128 (57) | 226 |
Luo et al. [64] | ER− and PgR− | - | Not Explicitly Reported | Not Reported |  ≥ 1% Nuclear | 38 (28) | 137 |
Niemeier et al. [15] | ER+/ER− |  ±  | Not Explicitly Reported | AR441 DAKO | H score > 10 | 151(80) | 189 |
Castellano et al. [65] | ER+ |  ±  | Primary Only | AR411 DAKO |  ≥ 1% | 609 (71) | 859 |
Hu et al. [28] | ER+/ER− |  ±  | Primary Only | AR411 DAKO |  ≥ 10% Nuclear | 1155 (79) | 1467 |
Loibl et al. [66] | ER+/ER− |  ±  | Primary Only | F39.4.1 BioGenex |  ≥ 1% | 358 (53) | 673 |
Park et al. [27] | ER+/ER− |  ±  | Not Explicitly Reported | AR441 Thermo Scientific |  ≥ 10% Nuclear | 541 (58) | 931 |
Yu et al. [67] | ER+/ER− |  ±  | Not Explicitly Reported | AR441 Lab Vision |  ≥ 10% Cytoplasmic | 237 (72) | 327 |
Gucalp et al. [49] | ER− and PgR− |  ±  | Primary and Metastases | AR411 DAKO |  ≥ 10% Nuclear | 51 (12) | 424 |
Honma et al. [68] | ER+/ER− |  ±  | Not Explicitly Reported | AR27 Novocastra |  ≥ 10% Nuclear | 212 (53) | 403 |
Tokunaga et al. [69] | ER+/ER− |  ±  | Primary Only | AR411 DAKO |  ≥ 75% Nuclear | 155 (62) | 250 |
Thike et al. [60] | ER− and PgR− | - | Not Explicitly Reported | AR27 NCL-AR-318 |  ≥ 1% Nuclear | 267 (38) | 699 |
Tsang et al. [70] | ER+/ER− |  ±  | Primary Only | AR441 DAKO |  ≥ 1% Nuclear | 549 (48) | 1144 |
Aleskandarany et al. [71] | ER+/ER− |  ±  | Not Explicitly Reported | Sc-816 Santa Cruz Biotech | H score ≥ 190 | 613 (54) | 1141 |
Bronte et al. [72] | ER+/ER− |  ±  | Primary and Metastases | SP107 Cell Marque Ventana Medical Systems |  ≥ 1% and ≥ 10% | 136 (83) and 131 (80) | 164 |
Candelaria et al. [73] | ER− and PgR− | - | Not Explicitly Reported | AR441 DAKO |  ≥ 10% | 45 (31) | 144 |
Kensler et al. [13] | ER+ |  ±  | Not Explicitly Reported | AR441 DAKO |  ≥ 1% Nuclear | 2475(82) | 3021 |
Xiang et al. [74] | ER+/ER− |  ±  | Primary Only | ZA-0554 ZSGB |  ≥ 10% Nuclear | 201 (67) | 298 |
Zhao et al. [75] | ER− and PgR− | – | Not Explicitly Reported | Abcam ab113273 | Not Reported | 60 (29) | 210 |